EUVIMEDEUVIMED entdecken
Crossref

Proteogenomic characterization of small cell lung cancer identifies biological insights and subtype-specific therapeutic strategies

Qian Liu, Jing Zhang, Chenchen Guo, Mengcheng Wang, Chenfei Wang, Yilv Yan, Liangdong Sun, Di Wang, Lele Zhang, Huansha Yu, Likun Hou, Chunyan Wu und 18 weitere

Cell · 2024-01 · 187 (1) · 184-203.e28

DOI: 10.1016/j.cell.2023.12.004 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cell, 2024-01. Verfasst von Qian Liu und 29 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai 200433, China; Department of Analytical …. Hauptthemen laut MEDLINE: Lung Neoplasms, Proteogenomics, Small Cell Lung Carcinoma. Die Arbeit wurde bisher 232-mal zitiert (Crossref) und nennt 140 Literaturangaben. Gefördert von: Chinese Academy of Sciences, Program of Shanghai Academic Research Leader, Science and Technology Commission of Shanghai Municipality.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We performed comprehensive proteogenomic characterization of small cell lung cancer (SCLC) using paired tumors and adjacent lung tissues from 112 treatment-naive patients who underwent surgical resection. Integrated multi-omics analysis illustrated cancer biology downstream of genetic aberrations and highlighted oncogenic roles of FAT1 mutation, RB1 deletion, and chromosome 5q loss. Two prognostic biomarkers, HMGB3 and CASP10, were identified. Overexpression of HMGB3 promoted SCLC cell migration via transcriptional regulation of cell junction-related genes. Immune landscape characterization revealed an association between ZFHX3 mutation and high immune infiltration and underscored a potential immunosuppressive role of elevated DNA damage response activity via inhibition of the cGAS-STING pathway. Multi-omics clustering identified four subtypes with subtype-specific therapeutic vulnerabilities. Cell line and patient-derived xenograft-based drug tests validated the specific therapeutic responses predicted by multi-omics subtyping. This study provides a valuable resource as well as insights to better understand SCLC biology and improve clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsProteogenomicsSmall Cell Lung CarcinomaHumansCell LineHeterograftsBiomarkers, Tumor

Stichwörter der Autor:innen

HMGB3ZFHX3 mutationlung cancermass spectrometryphosphoproteomicsprecision treatmentproteogenomicsproteomicssmall cell lung cancertumor subtyping

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Department of Thoracic Surgery, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai 200433, China; Department of Analytical Chemistry, State Key Laboratory of Drug Research, Shanghai Institute o…
  • Department of Thoracic Surgery, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai 200433, China.
  • State Key Laboratory of Cell Biology, Shanghai Institute of Biochemistry and Cell Biology, CAS Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, Shanghai 200031, China.
  • State Key Laboratory of Cell Biology, Shanghai Institute of Biochemistry and Cell Biology, CAS Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, Shanghai 200031, China; University of Chinese…
  • Key Laboratory of Spine and Spinal Cord Injury Repair and Regeneration of Ministry of Education, Department of Orthopedics, Tongji Hospital, School of Life Sciences and Technology, Tongji University, Shanghai 200092, Ch…
  • Central Laboratory, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai 200433, China.

Förderung

  • Chinese Academy of Sciences
  • Program of Shanghai Academic Research Leader
  • Science and Technology Commission of Shanghai Municipality
  • National Natural Science Foundation of China
  • Innovative Research Team of High-level Local University in Shanghai
  • Shanghai Municipal Education Commission
  • National Key Research and Development Program of China
  • Shanghai Pulmonary Hospital

Zitieren

APA

Liu, Q., Zhang, J., Guo, C., Wang, M., Wang, C., Yan, Y., Sun, L., Wang, D., Zhang, L., Yu, H., Hou, L., Wu, C., Zhu, Y., Jiang, G., Zhu, H., Zhou, Y., Fang, S., Zhang, T., Hu, L., …, & Zhang, P. (2024). Proteogenomic characterization of small cell lung cancer identifies biological insights and subtype-specific therapeutic strategies. Cell, 187(1), 184-203.e28. https://doi.org/10.1016/j.cell.2023.12.004

Vancouver

Liu Q, Zhang J, Guo C, Wang M, Wang C, Yan Y, et al. Proteogenomic characterization of small cell lung cancer identifies biological insights and subtype-specific therapeutic strategies. Cell. 2024;187(1):184-203.e28. doi:10.1016/j.cell.2023.12.004

BibTeX
@article{Liu2024,
  author = {Liu, Qian and Zhang, Jing and Guo, Chenchen and Wang, Mengcheng and Wang, Chenfei and Yan, Yilv and Sun, Liangdong and Wang, Di and Zhang, Lele and Yu, Huansha and Hou, Likun and Wu, Chunyan and Zhu, Yuming and Jiang, Gening and Zhu, Hongwen and Zhou, Yanting and Fang, Shanhua and Zhang, Tengfei and Hu, Liang and Li, Junqiang and Liu, Yansheng and Zhang, Hui and Zhang, Bing and Ding, Li and Robles, Ana I and Rodriguez, Henry and Gao, Daming and Ji, Hongbin and Zhou, Hu and Zhang, Peng},
  title = {Proteogenomic characterization of small cell lung cancer identifies biological insights and subtype-specific therapeutic strategies},
  journal = {Cell},
  year = {2024},
  volume = {187},
  number = {1},
  pages = {184--203.e28},
  doi = {10.1016/j.cell.2023.12.004}
}
Kostenlos starten →